Karleen F. Mcbride, PA

John Charlson is an Oncologist practicing medicine in Milwaukee, Wisconsin. Dr. Charlson is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Undifferentiated Pleomorphic Sarcoma. Dr. Charlson is board certified in Medical Oncology. Dr. Charlson is currently accepting new patients.

Dr. Kurzrock is a world-renowned leader in precision oncology and rare cancers research. She is the Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center, Associate Director of Precision Oncology at the Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine and the founding director of the Michels Rare Cancers Research Laboratories at the MCW Cancer Center. She is recognized as one of the world’s 25 most important voices in precision medicine and one of the most highly cited scientists globally. She has authored over 950 scientific and medical publications. Dr. Kurzrock is the Chair for the Early Therapeutics and Rare Cancers Committee (SWOG NCI) — one of the largest clinical trials cooperative groups in the country — and has been the principal investigator for more than 100 early-phase clinical trials, leading eight life-changing drugs to FDA approval. In 2022, Dr. Kurzrock and the DART rare cancer study team received the National Cancer Institute Director’s Award of Merit for outstanding work. Dr. Kurzrock is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum, Castleman Disease, Multicentric Castleman Disease (MCD), Lymphoid Hyperplasia, and Tissue Biopsy. Dr. Kurzrock is board certified in Internal Medicine and Medical Oncology. Dr. Kurzrock is currently accepting new patients.

Dustin Deming, MD, is a UW Health medical oncologist with a clinical emphasis on gastrointestinal cancers, including colon, rectal, anal, esophageal, liver and pancreatic cancers. He is also a professor at the University of Wisconsin School of Medicine and Public Health in the Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care. Dr. Deming is known for his commitment to delivering evidence‑based, compassionate care to patients facing complex cancer diagnoses.Dr. Deming’s research program focuses on developing improved treatments for specific subtypes of colon cancer and other gastrointestinal malignancies. His work centers on understanding how tumor‑specific genetic mutations influence treatment response, with the goal of creating personalized therapy regimens for individual patients. By using advanced animal models, his research helps bridge the gap between laboratory discoveries and clinical application.In addition to his translational research, Dr. Deming’s laboratory has developed innovative three‑dimensional cell culture techniques to advance clinical cancer research. He also leads efforts to identify new and improved biomarkers to better predict disease behavior and treatment outcomes. Through his combined roles as a clinician, researcher, and educator, Dr. Deming contributes to advancing precision oncology and improving care for patients with gastrointestinal cancers. Dr. Deming is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, PIK3CA-Related Overgrowth Spectrum, Familial Colorectal Cancer, Anal Cancer, and Liver Embolization. Dr. Deming is board certified in Internal Medicine and Medical Oncology. Dr. Deming is currently accepting new patients.